Render Target: SSR
Render Timestamp: 2025-03-06T19:05:59.645Z
Commit: 9fc0f116116d9da247dc8ddd4e5fe811153412e1
XML generation date: 2024-09-30 01:55:29.842
Product last modified at: 2025-02-18T20:30:09.239Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CRYAB (D6S9E) Rabbit mAb #45844

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 22
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CRYAB (D6S9E) Rabbit mAb recognizes endogenous levels of total CRYAB protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu165 of human CRYAB protein.

    Background

    CRYAB (αB-Crystallin) is a member of the small heat shock protein (sHSP also known as HSP20) family (1). This protein was initially found to be overexpressed in the eye lens, and later also detected at high levels in heart and skeletal muscle tissues (2,3). CRYAB functions mainly as a molecular chaperone, responding to stress by binding unfolded target proteins to prevent aggregation (4,5). Research studies have shown that elevated expression of CRYAB in neurological disease and stroke patients protects tissue and cells from damage under extreme stress, leading to the investigation of CRYAB as a potential therapeutic target (6-9). Researchers also found that expression of the missense mutation of CRYAB (R120G) in the mouse model causes cardiomyopathy due to abnormal desmin aggregation (10). At the molecular level, CRYAB is involved in multiple biological processes, such as inhibiting apoptosis by binding and inhibiting caspase and proapoptotic Bax and Bcl-xS protein functions (11,12), promoting angiogenesis by binding and stabilizing VEGF for secretion (13), and regulating cytoskeletal organization through association with actin filament, intermediate filament, and cardiac titin (14-16).
    1. Mehlen, P. et al. (1996) EMBO J 15, 2695-706.
    2. Piatigorsky, J. (1989) FASEB J 3, 1933-40.
    3. Bennardini, F. et al. (1992) Circ Res 71, 288-94.
    4. Benjamin, I.J. and McMillan, D.R. (1998) Circ Res 83, 117-32.
    5. Horwitz, J. (1992) Proc Natl Acad Sci U S A 89, 10449-53.
    6. Ousman, S.S. et al. (2007) Nature 448, 474-9.
    7. Ray, P.S. et al. (2001) FASEB J 15, 393-402.
    8. Arac, A. et al. (2011) Proc Natl Acad Sci U S A 108, 13287-92.
    9. Sanbe, A. (2011) Biol Pharm Bull 34, 1653-8.
    10. Wang, X. et al. (2001) Circ Res 89, 84-91.
    11. Kamradt, M.C. et al. (2001) J Biol Chem 276, 16059-63.
    12. Mao, Y.W. et al. (2004) Cell Death Differ 11, 512-26.
    13. Kase, S. et al. (2010) Blood 115, 3398-406.
    14. Wang, K. and Spector, A. (1996) Eur J Biochem 242, 56-66.
    15. Nicholl, I.D. and Quinlan, R.A. (1994) EMBO J 13, 945-53.
    16. Zhu, Y. et al. (2009) J Biol Chem 284, 13914-23.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.